-

04:43:20 PM

ATHA Stock News

ATHA - Athira Pharma Inc

01/07/21 7:30 AM

Nasdaq : ATHA

conferences

Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive

RHEA-AI

neutral

12/14/20 7:30 AM

Nasdaq : ATHA

management

Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors.

RHEA-AI

neutral

12/08/20 7:30 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it has been awarded a research grant expected to total $15

RHEA-AI

neutral

12/01/20 7:30 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2

RHEA-AI

neutral

11/12/20 4:05 PM

Nasdaq : ATHA

earnings

Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights

- LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, 2020 SEATTLE, Nov. 12, 2020

RHEA-AI

neutral

11/10/20 7:30 AM

Nasdaq : ATHA

conferences

Athira Pharma to Present at Upcoming November Investor Conferences

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer,

RHEA-AI

neutral

10/21/20 7:30 AM

Nasdaq : ATHA

conferences

Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments

RHEA-AI

neutral

10/08/20 7:30 AM

Nasdaq : ATHA

management

Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to the company's Board of

RHEA-AI

neutral

10/01/20 7:30 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal

RHEA-AI

positive

09/22/20 4:05 PM

Nasdaq : ATHA

IPOoffering

Athira Pharma Announces Closing of Initial Public Offering

Athira Pharma, Inc., (Nasdaq: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the closing of its initial public offering of

RHEA-AI

neutral

Prev 3 4 5 6 7 8 9 Next

ATHA Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttps://www.athira.com
Security nameAthira Pharma Inc
Issue typecs
SectorManufacturing
Sic code2836
Tags
- Commercial Services
- Miscellaneous Commercial Services
- Health Technology
- Biotechnology
- Manufacturing
- Medicinal and Botanical Manufacturing

About Athira Pharma Inc

Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia.